Hence, the aim of this study is to evaluate the role of systemic inflammation measured by CRP as well as the NLR, PLR, and SII on response and survival in R/M-HNSCC treated by single-agent Nivolumab and Pembrolizumab therapy. Here, CRP is linked to head and neck squamous cell carcinoma.